This gives me the average analyst price target ($188.55) vs current price ($183.14 mentioned, close to actual $184.37). That's a good data point. I have enough to write a comprehensive preview now.# Globe Life Inc. (NYSE: GL) — Q2 2026 Earnings Preview

Report date: Results expected after market close Wednesday, July 22, 2026, with the earnings call the following morning (July 23, 11:00 a.m. ET). Current share price: ~$184 (all-time/52-week high territory).

---

1. Setup: A stock that has run hard into the print

GL shares have been one of the stronger stories in insurance this year, rallying from roughly $138 in early January to ~$184 today — a move that accelerated sharply from mid-June ($152) into mid-July. Sentiment has been reinforced by a string of sell-side price-target hikes ahead of the print: Piper Sandler recently raised its target to $200 (Overweight) and JPMorgan moved to $201, while the current Street average sits around $174–$189, leaving relatively modest implied upside versus where the stock trades today after this run. That backdrop raises the bar for tomorrow's print — a "good" quarter may simply confirm the rally, while any wobble in agent-count trends, margins, or guidance could trigger outsized multiple compression given how far expectations have already been marked up.

2. What the Street is looking for

• EPS: Consensus is centered around $3.66–$3.67 in operating EPS, up roughly 12% year-over-year from $3.27 a year ago.
• Revenue: Expected around $1.6 billion, consistent with the ~6–7% total premium growth trajectory the company has guided to for the full year.
• Track record: GL missed Q1 2026 operating EPS consensus of $3.46 by reporting $3.43 (a small ~$0.03 miss), even though net operating income still grew 12% y/y and management raised full-year guidance — a reminder that even solid underlying results can occasionally disappoint against elevated Street numbers.

3. Full-year 2026 guidance to reconcile against

Coming out of Q1, management raised full-year 2026 net operating EPS guidance to $15.40–$15.90 (up $0.35 at the midpoint), implying roughly 8% growth at the midpoint. Key guidance pillars investors should track for confirmation or revision this quarter:

Metric	FY26 Guidance
Total premium growth	~7%
Life premium growth	3.0%–3.5%
Life underwriting margin	42%–45% full year; ~41% normalized in Q2 (spike to 49%–54% expected in Q3 from assumption updates)
Health premium growth	14%–17%
United American health margin	8%–9% full year (but ~10% average over final 3 quarters)
Admin expense ratio	~7.3% of premium
Excess investment income growth	4.0%–4.5%
Share repurchases	$560M–$610M
Shareholder dividends	~$90M (reflecting a 22% dividend rate hike)
RBC ratio target	300%–320%

Because Q2 is explicitly guided to a ~41% normalized life margin (before the anticipated Q3 assumption-update boost), the print itself should look fairly "clean" — the real fireworks (an estimated $70–$110 million pre-tax benefit) are earmarked for Q3, not Q2. Investors should watch whether management narrows or reaffirms that Q3 assumption-update range on the call, since it's already a major swing factor embedded in the raised full-year guide.

4. Segment/operational threads to watch

• Agent count recovery at American Income Life (AIL): Q1 saw AIL's average producing agent count down 4% y/y due to weaker new-agent retention, even as sales/margins grew. Management implemented compensation changes at the start of Q2 specifically to re-incentivize recruiting and retention, and guided that these changes should start showing up in agent count growth in the second half of 2026. This quarter's agent-count trend is arguably the single most important KPI to confirm the turnaround thesis is on track, versus Liberty National and Family Heritage, which are already showing double-digit agent growth.
• United American / Medicare Supplement: Health sales at UA nearly tripled in Q1 (up 122% y/y) on Medicare Advantage-to-Medicare Supplement migration tailwinds and new premium rate increases. Management guided full-year UA sales to "high teens" growth (raised from a prior "flat" outlook) but flagged decelerating growth into Q4 given a tough comp. Q2 should start to show the benefit of ~$20M/quarter in incremental rate-increase premium flowing through, supporting margin improvement toward the ~25%+ health margin range guided for the remaining quarters.
• Mortality/lapse trends: Favorable mortality (heart/circulatory, non-lung cancer, and notably improving "non-medical" causes like drug/alcohol and suicide) has been driving remeasurement gains and is the basis for the anticipated Q3 assumption update. Watch for continuation of these trends, along with commentary on elevated lapse rates (particularly at AIL), which management has attributed to macro/affordability pressure and business mix (worksite, DTC internet channel) rather than a broad deterioration.
• Capital returns: GL front-loaded buybacks in Q1 (accelerating to $205M when shares dipped below $140) and raised full-year buyback guidance to $560–$610M alongside a 22% dividend increase. Watch pace of Q2 repurchases now that shares trade well above that opportunistic entry point.
• Bermuda reciprocal jurisdiction: Management said it expected to file for reciprocal jurisdiction status in Q2 and promised a more substantive update on this call — a structural capital-efficiency initiative worth monitoring for updated cash-flow/reinsurance implications.

5. Overhangs investors shouldn't ignore

• Litigation legacy from the 2024 short-seller episode: GL's stock famously fell sharply after an April 2024 report from short-seller Fuzzy Panda Research alleging "extensive allegations of insurance fraud ignored by management despite being obvious and reported hundreds of times," including policies written for dead and fictitious people. GL publicly refuted the report, calling it "deliberately false, misleading and defamatory". That episode continues to generate legal tail risk: a federal judge in the Eastern District of Texas denied Globe Life's motion to dismiss the consolidated securities fraud lawsuit, finding shareholders had "adequately alleged securities fraud claims", and additional shareholder derivative suits (including a September 2025 filing) remain pending, largely deriving from the same short-seller reports. Separately, the SEC's Fort Worth office has requested information related to the short-seller allegations, though as of the last annual report no claims had been asserted. This quarter's Q1 results already reflected ~$1.8M of after-tax legal-proceedings costs — a manageable but non-zero and recurring line item to watch.
• Insider selling alongside the dividend hike: Recent Form 4 filings show Chief Strategy Officer Michael Majors trimming his position (reducing his stake by 30,000 shares, ~$4.4M, since February) even as the board raised the dividend — a combination some observers have flagged as a mixed signal worth monitoring, even if not necessarily predictive of operating performance.
• Valuation risk after the re-rating: With shares near record highs and average analyst price targets only modestly above the current quote, the stock now needs continued execution (agent growth inflection, margin discipline, Q3 assumption-update delivery) to justify further multiple expansion — leaving less room for error than earlier in the year.

6. Bottom line for tomorrow

The bar is a "clean," roughly 41% normalized life margin, low-teens health margin uplift, and confirmation that AIL's compensation fix is starting to bend agent-count trends positively heading into the second half. Given the stock's steep run into the print and full-year guidance that already bakes in a large Q3 assumption-update tailwind, the market's focus tomorrow is likely less about the Q2 number itself (which is expected to be a solid ~12% EPS growth quarter) and more about (1) any update/reaffirmation of the Q3 assumption-update magnitude, (2) tangible evidence of the AIL agent-count inflection, (3) capital-return pacing, and (4) any incremental color on the pending securities litigation and Bermuda initiative.